News Breaks |
|
|
| February 1, 2013 |
| 06:20 EDT |  | GILD, INFI, ARIA | Gilead seeks more blood cancer drug deals, Bloomberg reports
Gilead Sciences (GILD) has spent $1.2B in two years to buy blood cancer drugs, and wants more, reports Bloomberg. Treatment for leukemia and other blood cancers is one of the fastest growing markets for cancer drugs. Gilead COO John Milligan said the company is eyeing possible new deals. They could include Ariad Pharmaceuticals (ARIA) and Infinity Pharmaceuticals (INFI), said Raghuram Selvaraju, at Aegis Capital Corp. Reference Link |
|
|
News For GILD;ARIA;INFI From The Last 14 Days Check below for free stories on GILD;ARIA;INFI the last two weeks. |
|
|
| June 18, 2013 |
| 11:20 EDT |  | INFI | Infinity Pharmaceuticals shares up 11%, or $1.97, to $19.14
 Subscribe for More Information |
|
| 07:28 EDT |  | GILD | Wells Faro to host a conference
Subscribe for More Information |
|
| June 17, 2013 |
| 16:00 EDT |  | GILD | Options Update; June 17, 2013
Subscribe for More Information |
|
| 06:25 EDT | | GILD | Gilead reports interim Phase 2 data for Idelalisib
Gilead announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6%, with a median duration of response at this interim analysis of 11.9 months. The most common Grade ≥3 adverse event was diarrhea . Grade ≥3 transaminase elevations were reported via central laboratory testing in 13% of patients; Grade ≥3 neutropenia occurred in 26% of patients. Sixteen percent of patients discontinued due to adverse events. |
|
| June 13, 2013 |
| 10:05 EDT |  | GILD | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:33 EDT | | GILD | Gilead upgraded to Buy from Hold at Argus
Subscribe for More Information |
|
| June 11, 2013 |
| 07:41 EDT | | ARIA | ARIAD initiates Phase 2 trial of Iclusig
Subscribe for More Information |
|
| 07:27 EDT | | ARIA | William Blair to host a conference
Subscribe for More Information |
|
| 06:08 EDT | | INFI | Stocks with implied volatility below IV index mean; MBI INFI
Stocks with implied volatility below IV index mean; MBIA (MBI), Infinity Pharmaceuticals (INFI) according to IVolatility. |
|
| June 10, 2013 |
| 11:40 EDT | | INFI | Options with decreasing implied volatility: TIVO INFI NBG UNXL FRAN
|
| |
| 07:40 EDT | | GILD, INFI | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information |
|
| 07:19 EDT |  | INFI | Infinity Pharmaceuticals weakness an overreaction, says Stifel
After meeting with Infinity's management, Stifel views weakness in the shares following ASCO data as an overreaction. The firm thinks that the ASCO data reaffirmed that IPI-145 is an active drug in iNHL and CLL, and it views the drug as competitive with other hematological malignancy drugs that are being developed. The firm keeps a Buy rating on the stock. |
|
| 06:38 EDT | | INFI | Stocks with implied volatility below IV index mean; MBI INFI
Stocks with implied volatility below IV index mean; MBIA (MBI), Infinity Pharmaceuticals (INFI) according to IVolatility. |
|
| June 7, 2013 |
| 17:21 EDT | | GILD | Gilead announces U.S. FDA priority review designation for Sofosbuvir
Subscribe for More Information |
|
| 11:56 EDT | | INFI | Options with decreasing implied volatility: TIVO INFI NBG UNXL
Subscribe for More Information |
|
| 08:17 EDT | | ARIA | ARIAD has a conference call hosted by JPMorgan
Subscribe for More Information |
|
| 06:00 EDT | | INFI | Stocks with implied volatility below IV index mean; CSCO INFI
Subscribe for More Information |
|
| June 6, 2013 |
| 12:04 EDT | | INFI | Options with decreasing implied volatility: INFI FRAN GES ANN OVTI
|
|
| 09:07 EDT | | GILD | Gilead Sofosbuvir likely to be granted priority review, says RBC Capital
Subscribe for More Information |
|
| 08:27 EDT | | GILD | Bernstein's biotech analysts hold an analyst/industry conference call
Subscribe for More Information |
| |
|
|
|
|
